R.J.H.M. van der Straaten

Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis

H M Albers, Judith A.M. Wessels, R.J.H.M. van der Straaten et al. · Arthritis Care & Research · 2008 · 136 citations

Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study

Hans Gelderblom, Jean‐Yves Blay, Beatrice Seddon et al. · European Journal of Cancer · 2013 · 41 citations · Full text

Brostallicin Versus Doxorubicin, Phase Ii, Medicine +9

Association of ABCB1, 5-HT3B Receptor and CYP2D6 Genetic Polymorphisms with Ondansetron and Metoclopramide Antiemetic Response in Indonesian Cancer Patients Treated with Highly Emetogenic Chemotherapy

Dyah Aryani Perwitasari, Judith A.M. Wessels, R.J.H.M. van der Straaten et al. · Japanese Journal of Clinical Oncology · 2011 · 39 citations · Full text

Arsenic metabolites affect expression of the neurofilament and tau genes: An in-vitro study into the mechanism of arsenic neurotoxicity

A. Vahidnia, R.J.H.M. van der Straaten, Fred P.H.T.M. Romijn et al. · Toxicology in Vitro · 2007 · 38 citations

Neurodegenerative Diseases, Biochemistry, Tau Genes +11

Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease

Maurits E. L. Arbouw, Kris L. L. Movig, Toine C. G. Egberts et al. · European Journal of Clinical Pharmacology · 2009 · 29 citations · Full text